Anterogen.Co.Ltd (KQ:065660) — Stock Price
Anterogen.Co.Ltd (KQ:065660) is currently trading at ₩16410.00 KRW, down 3.07% today. Over the past 52 weeks, shares have ranged between ₩14930.00 and ₩58000.00. This page tracks Anterogen.Co.Ltd's live share price on the KQ exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see Anterogen.Co.Ltd stock valuation.
Anterogen.Co.Ltd (065660) Stock Price Chart — Daily History & Trading Volume
The chart below tracks Anterogen.Co.Ltd's daily closing share price and trading volume on the KQ exchange over the past year, giving a clear view of recent price momentum and liquidity.
Anterogen.Co.Ltd Income Statement — Revenue, Profit & Earnings by Year
Anterogen.Co.Ltd's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Total Revenue | ₩6.93 Billion | ₩6.50 Billion | ₩6.59 Billion | ₩8.12 Billion | ₩4.15 Billion |
| Cost of Revenue | ₩4.30 Billion | ₩3.83 Billion | ₩3.97 Billion | ₩4.25 Billion | ₩2.41 Billion |
| Gross Profit | ₩2.63 Billion | ₩2.67 Billion | ₩2.62 Billion | ₩3.87 Billion | ₩1.74 Billion |
| Research & Development | ₩4.11 Billion | ₩5.38 Billion | ₩4.66 Billion | ₩4.19 Billion | ₩4.01 Billion |
| SG&A | ₩1.99 Billion | ₩1.90 Billion | ₩2.14 Billion | ₩1.87 Billion | ₩1.29 Billion |
| Total Operating Expenses | ₩10.68 Billion | ₩11.57 Billion | ₩11.24 Billion | ₩10.75 Billion | ₩7.86 Billion |
| Operating Income | ₩-3.80 Billion | ₩-5.46 Billion | ₩-4.63 Billion | ₩-2.63 Billion | ₩-2.74 Billion |
| EBITDA | — | — | — | — | — |
| EBIT | — | — | — | ₩-2.63 Billion | ₩-3.74 Billion |
| Interest Expense | ₩259.60 Million | ₩1.53 Billion | ₩1.69 Billion | ₩1.24 Billion | ₩315.43 Million |
| Income Before Tax | ₩-2.29 Billion | ₩-2.84 Billion | ₩-6.85 Billion | ₩-553.98 Million | ₩-4.38 Billion |
| Income Tax Expense | — | — | — | — | — |
| Net Income | ₩-2.29 Billion | ₩-2.84 Billion | ₩-6.84 Billion | ₩-553.98 Million | ₩-4.38 Billion |
Anterogen.Co.Ltd Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes Anterogen.Co.Ltd's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Total Assets | ₩116.08 Billion | ₩149.43 Billion | ₩124.13 Billion | ₩136.70 Billion | ₩94.20 Billion |
| Total Current Assets | ₩45.08 Billion | ₩56.38 Billion | ₩62.45 Billion | ₩65.36 Billion | ₩54.91 Billion |
| Cash & Equivalents | — | — | ₩3.90 Billion | ₩6.97 Billion | ₩40.11 Billion |
| Short-term Investments | ₩38.17 Billion | ₩48.95 Billion | ₩52.07 Billion | ₩52.04 Billion | ₩7.81 Billion |
| Net Receivables | ₩2.55 Billion | ₩2.28 Billion | ₩2.73 Billion | ₩4.08 Billion | ₩1.66 Billion |
| Inventory | ₩1.09 Billion | ₩1.91 Billion | ₩2.01 Billion | ₩1.28 Billion | ₩2.21 Billion |
| Property, Plant & Equipment | — | — | ₩23.09 Billion | ₩22.43 Billion | ₩19.85 Billion |
| Goodwill | ₩5.72 Billion | ₩5.72 Billion | ₩5.72 Billion | — | — |
| Total Liabilities | ₩5.87 Billion | ₩19.99 Billion | ₩17.34 Billion | ₩19.83 Billion | ₩13.14 Billion |
| Total Current Liabilities | ₩1.48 Billion | ₩10.76 Billion | ₩15.04 Billion | ₩13.75 Billion | ₩11.69 Billion |
| Long-term Debt | — | — | — | — | — |
| Net Debt | — | ₩8.35 Billion | ₩8.81 Billion | ₩4.80 Billion | ₩774.02 Million |
| Total Stockholder Equity | ₩110.21 Billion | ₩129.44 Billion | ₩106.79 Billion | ₩116.87 Billion | ₩81.07 Billion |
| Retained Earnings | ₩-10.43 Billion | ₩-8.16 Billion | ₩-5.22 Billion | ₩-520.93 Million | ₩-16.45 Billion |
Anterogen.Co.Ltd Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how Anterogen.Co.Ltd generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Operating Cash Flow | ₩-860.38 Million | ₩-1.99 Billion | ₩-1.98 Billion | ₩-3.05 Billion | ₩-4.41 Billion |
| Capital Expenditures | ₩311.59 Million | ₩203.28 Million | ₩1.48 Billion | ₩3.33 Billion | ₩5.72 Billion |
| Free Cash Flow | ₩-1.17 Billion | ₩-2.19 Billion | ₩-3.46 Billion | ₩-6.58 Billion | ₩-10.15 Billion |
| Investing Cash Flow | ₩10.94 Billion | ₩4.51 Billion | ₩-4.90 Million | ₩-14.37 Billion | ₩-1.05 Billion |
| Financing Cash Flow | ₩-10.00 Billion | ₩-5.00 Billion | ₩-1.01 Billion | ₩15.92 Billion | ₩3.50 Billion |
| Dividends Paid | — | — | — | — | — |
| Stock-Based Compensation | ₩32.42 Million | ₩98.66 Million | ₩49.35 Million | — | ₩39.75 Million |
| Depreciation | ₩524.98 Million | ₩605.35 Million | ₩523.51 Million | ₩827.24 Million | ₩615.76 Million |
| Change in Cash | ₩95.21 Million | ₩-2.51 Billion | ₩-3.07 Billion | ₩-1.51 Billion | ₩-1.96 Billion |
Anterogen.Co.Ltd Earnings History — EPS Actual vs. Analyst Estimates
Track Anterogen.Co.Ltd's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
| Report Date | EPS Actual | EPS Estimate | Surprise |
|---|---|---|---|
| Sep 30, 2025 | -7.93 | — | — |
| Jun 30, 2025 | -9.01 | — | — |
| Mar 31, 2025 | -70.54 | — | — |
| Dec 31, 2024 | -107.12 | — | — |
| Sep 30, 2024 | -16.69 | — | — |
| Jun 30, 2024 | -53.23 | — | — |
| Mar 31, 2024 | -58.72 | — | — |
| Dec 31, 2023 | -19.59 | — | — |